Abbott Narrows Its Outlook as COVID-19 Testing Demand Wanes. Its Stock Is Falling. [Yahoo! Finance]
Abbott Laboratories (ABT)
Last abbott laboratories earnings: 4/16 07:30 am
Check Earnings Report
US:NYSE Investor Relations:
abbott.com/investors.html
Company Research
Source: Yahoo! Finance
COVID-19 test sales in the second quarter dropped 46% from the year before. Second-quarter earnings and revenue exceeded analysts' estimates. Abbott Laboratories ( ABT ) shares slumped Thursday after the drugmaker narrowed its full-year outlook, even as it posted better-than-expected quarterly results, as demand for COVID-19 tests declines. The shares were down over 8% in recent trading, among the worst performers in the S&P 500. Still, they've added about 7% since the start of the year. The company said it now sees full-year adjusted earnings per share of $5.10 to $5.20, compared to its previous outlook of $5.05 to $5.25 per share. In the second quarter, sales at Abbott's Diagnostics unit dropped 1% year-over-year to $2.28 billion, dragged down by COVID-19 testing sales, which slid 46% to $55 million. Its Nutrition segment's sales were up 2.9% to $2.21 billion, and they grew 6.9% to $1.38 billion at its Established Pharmaceuticals division. Overall, second-quarter adjust
Show less
Read more
Impact Snapshot
Event Time:
ABT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ABT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ABT alerts
High impacting Abbott Laboratories news events
Weekly update
A roundup of the hottest topics
ABT
News
- Abbott Laboratories (NYSE:ABT) had its "buy (b-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Is Abbott Laboratories Attractively Priced After Recent Share Price Gains And DCF Concerns? [Yahoo! Finance]Yahoo! Finance
- Abbott's Volt™ Pulsed Field Ablation System Receives FDA Approval to Treat Patients with Atrial Fibrillation [Yahoo! Finance]Yahoo! Finance
- Abbott's Volt™ Pulsed Field Ablation System Receives FDA Approval to Treat Patients with Atrial FibrillationPR Newswire
- Investors in Abbott Laboratories (NYSE:ABT) have seen returns of 27% over the past five years [Yahoo! Finance]Yahoo! Finance
ABT
Earnings
- 10/15/25 - In-Line
ABT
Sec Filings
- 12/23/25 - Form 3
- 12/19/25 - Form 3
- 12/12/25 - Form 4
- ABT's page on the SEC website